Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial

Ophthalmic Surg Lasers Imaging Retina. 2013 Sep-Oct;44(5):465-70. doi: 10.3928/23258160-20130909-08.

Abstract

Background and objective: To evaluate 810-nm subthreshold diode micropulse (SDM) laser in patients with chronic central serous chorioretinopathy (CSC).

Patients and methods: Prospective, randomized, double-blind, sham-controlled pilot trial. Patients were randomized to SDM laser treatment (group 1) or sham procedure (group 2). Primary outcome measure was change in best corrected visual acuity (BCVA); secondary outcome was central macular thickness after 3 months. Laser treatment was performed along the detached area. At the 3-month visit, all patients were evaluated for re-treatment if they met re-treatment criteria.

Results: Fifteen patients were included in this study: five patients in the sham group and 10 in the treatment group. At 3 months, BCVA was significantly enhanced in the treatment group (P = .006) compared with the sham group (P = .498). All patients from the sham group needed treatment after 3 months. An improvement in central macular thickness and leakage on fluorescein angiography was noted in all treated patients (in both groups).

Conclusion: In this limited-size, short-term exploratory study, SDM laser was effective in treating chronic CSC. There was no evidence of retinal damage induced by treatment.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Central Serous Chorioretinopathy / surgery*
  • Chronic Disease
  • Double-Blind Method
  • Female
  • Humans
  • Laser Coagulation / methods*
  • Lasers, Semiconductor*
  • Male
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Visual Acuity